Pfizer (Japan)
In research, Pfizer (Japan) stands highest in Medicine (#9,024 of 17,978 worldwide), Health Sciences (#11,910 of 20,462 worldwide) and Life Sciences (#10,956 of 14,347 worldwide), over all time.
- World rank, 2022–2025
- #18,781 of 28,054 · #23,466 all time
- Rank in Japan
- #523 of 1,070
- Research works
- 439 ▲ 16% vs 2013–17
- Citations
- 8k 18.1 per fractional work
- Top-10% rate
- 18.2% record average 16.5%
- Open access
- 50% world 28%
What is Pfizer (Japan) known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| MedicineField | #9,024 of 17,978 | 16.2% | 229 | |
| Health SciencesDomain | #11,910 of 20,462 | 16.1% | 236 | |
| Life SciencesDomain | #10,956 of 14,347 | 13.2% | 122 |
Each strip is that field’s whole ranked pool, with the notch where Pfizer (Japan) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 12.2×. Every wedge is a field page.
- Pharmacology, Toxicology and Pharmaceutics 12.2×
- Immunology and Microbiology 4.7×
- Medicine 3.2×
- Economics, Econometrics and Finance 2.8×
- Mathematics 1.9×
- Biochemistry, Genetics and Molecular Biology 1.7×
- Decision Sciences 1.6×
- Health Professions 0.7×
- Psychology 0.6×
- Neuroscience 0.5×
- Chemistry 0.5×
- Nursing 0.5×
- Computer Science 0.3×
- Environmental Science 0.1×
- Social Sciences 0.1×
- Business, Management and Accounting 0.1×
- Engineering 0.1×
- Agricultural and Biological Sciences 0.0×
- Arts and Humanities 0.0×
Who are the top researchers at Pfizer (Japan)?
Ranked on the composite score, Yoko Fujimoto lead among researchers whose main affiliation is Pfizer (Japan).
- 1 Yoko Fujimoto Japan · #1,458,156 worldwide 9 citations · 21 works
Which keywords describe research at Pfizer (Japan)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Epidemiology, Clinical Trials, Breast Cancer, Inflammation, Diagnosis, Quality of Life, Pharmaceutical Industry and Treatment.
- Palbociclib
- Disease-Modifying Antirheumatic Drugs
- Biological Therapy
- Respiratory Syncytial Virus
- Gene Therapy
- Anticoagulant Therapy
- Viral Infections
- Antimicrobial Resistance
- Thrombosis
- Vaccine Development
- Pathogenesis
- Cytokines
- Guidelines
- Health Utility Measures
- Prophylaxis
- Pharmaceutical Industry
- Pandemic
- Diagnosis
- Clinical Trials
- Inflammation
- Epidemiology
- Quality of Life
- Treatment
- Breast Cancer
- Clinical Practice Guidelines
- Chemotherapy
- Cost-effectiveness Analysis
- Autoantibodies
- Cardiovascular Risk
- Metastatic Breast Cancer
- SARS-CoV-2
- Monoclonal Antibodies
- Adverse Drug Reactions
- Recombinant Factor VIIa
- ACE2 Receptor
- Efficacy
- Human Metapneumovirus
- Rheumatoid Arthritis
- CDK4/6 Inhibitors
- Mutation
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology11▲ 3.8×43 topics
- Inflammation5▲ 3.1×19 topics
- Quality of Life4▲ 3.7×9 topics
- Clinical Trials4▲ 7.9×8 topics
- Treatment4▲ 4.0×16 topics
- Diagnosis4▲ 5.0×12 topics
- Breast Cancer3▲ 19×8 topics
- Pandemic3▲ 3.4×5 topics
- Clinical Practice Guidelines3▲ 6.6×7 topics
- Pharmaceutical Industry3▲ 94×2 topics
- Chemotherapy2▲ 4.8×10 topics
- Prophylaxis2▲ 25×2 topics
- Cost-effectiveness Analysis2▲ 35×1 topic
- Health Utility Measures2▲ 35×1 topic
- Autoantibodies2▲ 13×5 topics
- Guidelines2▲ 6.3×4 topics
- Cardiovascular Risk2▲ 8.8×3 topics
- Cytokines2▲ 9.6×2 topics
- Metastatic Breast Cancer2▲ 49×2 topics
- Pathogenesis2▲ 5.5×9 topics
- SARS-CoV-22▲ 8.5×4 topics
- Vaccine Development2▲ 11×4 topics
- Monoclonal Antibodies2▲ 29×3 topics
- Thrombosis2▲ 9.4×5 topics
- Adverse Drug Reactions2▲ 46×3 topics
- Antimicrobial Resistance2▲ 12×4 topics
- Recombinant Factor VIIa2▲ 56×2 topics
- Viral Infections2▲ 45×2 topics
- ACE2 Receptor2▲ 9.9×2 topics
- Anticoagulant Therapy2▲ 19×2 topics
- Efficacy2▲ 32×2 topics
- Gene Therapy2▲ 12×3 topics
- Human Metapneumovirus2▲ 53×1 topic
- Respiratory Syncytial Virus2▲ 53×1 topic
- Rheumatoid Arthritis2▲ 24×3 topics
- Biological Therapy2▲ 40×1 topic
- CDK4/6 Inhibitors2▲ 90×1 topic
- Disease-Modifying Antirheumatic Drugs2▲ 45×1 topic
- Mutation2▲ 12×3 topics
- Palbociclib2▲ 90×1 topic
Which research topics does Pfizer (Japan) publish most on?
By volume in 2022–2025: Health Systems, Economic Evaluations, Quality of Life, Respiratory viral infections research, Advanced Breast Cancer Therapies and Rheumatoid Arthritis Research and Therapies.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 2 works
- 2 Respiratory viral infections research Epidemiology 2 works
- 3 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 2 works
- 4 Rheumatoid Arthritis Research and Therapies Rheumatology 2 works
- 5 Pharmaceutical Economics and Policy Economics and Econometrics 2 works
- 6 Hemophilia Treatment and Research Hematology 2 works
- 7 Biosimilars and Bioanalytical Methods Immunology 2 works
- 8 Migraine and Headache Studies Psychiatry and Mental health 1 works
- 9 Atrial Fibrillation Management and Outcomes Cardiology and Cardiovascular Medicine 1 works
- 10 Pneumonia and Respiratory Infections Epidemiology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Pfizer (Japan)'s research output changed?
Output in 2018–2022 was 16% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Tokyo
- The University of Tokyo
- Tokyo Institute of Technology
- Keio University
- Waseda University
- Tokyo University of Science
- Nihon University
- Hitachi (Japan)
- NTT (Japan)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.